Background Thiamine is a precursor of the essential coenzyme thiamine pyrophosphate required for glucose metabolism; it improves the immune system function and has shown to reduce the risk of several diseases. The role of thiamine in critically ill septic patient has been addressed in multiple studies; however, it’s role in COVID-19 patients is still unclear. The aim of this study was to evaluate the use of thiamine as an adjunctive therapy on mortality in COVID-19 critically ill patients. Methods This is a two-center, non-interventional, retrospective cohort study for critically ill patients admitted to intensive care units (ICUs) with a confirmed diagnosis of COVID19. All patients aged 18 years or older admitted to ICUs between March 1, 2020, and December 31, 2020, with positive PCR COVID-19 were eligible for inclusion. We investigated thiamine use as an adjunctive therapy on the clinical outcomes in critically ill COVID-19 patients after propensity score matching. Results A total of 738 critically ill patients with COVID-19 who had been admitted to ICUs were included in the study. Among 166 patients matched using the propensity score method, 83 had received thiamine as adjunctive therapy. There was significant association between thiamine use with in-hospital mortality (OR = 0.39; 95% CI 0.19–0.78; P value = 0.008) as well as the 30-day mortality (OR = 0.37; 95% CI 0.18–0.78; P value = 0.009). Moreover, patients who received thiamine as an adjunctive therapy were less likely to have thrombosis during ICU stay [OR (95% CI) 0.19 (0.04–0.88), P value = 0.03]. Conclusion Thiamine use as adjunctive therapy may have potential survival benefits in critically ill patients with COVID-19. Additionally, it was associated with a lower incidence of thrombosis. Further interventional studies are required to confirm these findings.

Objective To investigate the correlation between the ABO blood group and the risk of recurrent catheter-associated urinary tract infections (CA-UTI) and multi-drug resistant (MDR) organism reinfection in the critically ill. Methods This retrospective cohort study enrolled adult patients admitted to the intensive care unit (ICU) with confirmed CA-UTI to investigate the correlation between ABO type and the susceptibility to recurrent, reinfection and MDR reinfection. Patients were classified into two groups based on ABO type (O blood group versus non-O blood group). Results A total of 81 patients were included in the study: 37 in the O blood group and 44 in the non-O blood group. Patients in the O blood group were associated with significantly lower odds of recurrent CA-UTI (adjusted odds ratio 0.28; 95% confidence interval 0.08, 0.95), a shorter ICU length of stay (LOS) (estimate [SE] –0.24 [0.05]), hospital LOS (estimate [SE] –0.15 [0.03]) and mechanical ventilation duration (estimate [SE] –0.41 [0.07]) compared with the non-O blood group type. Conclusion Non-O blood group type might be a risk factor for recurrent CA-UTI and infection with MDR organism.

Background: Thiamine is a precursor of the essential coenzyme thiamine pyrophosphate (TPP) required for glucose metabolism; it improves the immune system function and has been shown to reduce the risk of several diseases. The role of thiamine in COVID-19 critically ill patients is still unclear, however, its role in the critically ill septic patient has been addressed in multiple studies. The objective of this study was to evaluate the use of thiamine as adjunctive therapy on the mortality in COVID 19 critically ill patients. Methods: This is a multicenter, non-interventional, retrospective cohort study for all critically ill patients admitted to intensive care units (ICUs) with a confirmed diagnosis of COVID19. All patients aged 18 years or older who were admitted to ICUs between March 1st to December 31st, 2020 with positive PCR COVID-19 were included in the study. We investigated the association between thiamine use as an adjunctive therapy and clinical outcomes in COVID -19 after propensity score matching using baseline severity scores, systemic use of corticosteroids and study centers. Results: A total of 738 critically ill patients with COVID-19 who had been admitted in ICUs at the two governmental hospitals included in the study. Among 166 patients matched using propensity score, 83 had received thiamine as adjunctive therapy. There was significant association between thiamine use with in-hospital mortality (OR=0.49; 95% CI = 0.25- 0.97; P=0.04) as well with 30-day ICU mortality (OR=0.45; 95% CI = 0.215- 0.935; P=0.03). Moreover, patients who received thiamine as an adjunctive therapy were less likely to have thrombosis during ICU stay by 81 % (OR (95%CI): 0.19 (0.040,0.884), p-value=0.034).Conclusion: Thiamine use as an adjunctive therapy may have potential survival benefits in critically ill patients with COVID-19.

Background: CA-UTI consider one of the most common hospital acquired infections. Several risk factors for CA-UTI have been identified. There is no enough evidence regard the impact of ABO type and the risk of CA-UTI acquisition. The aim of this study is to investigate the correlation between ABO types and the risk of having recurrent, reinfection CA-UTI, and MDR reinfection in critically ill.Methodology: A retrospective cohort study of adult ICU patients through 2018 in ICU at tertiary hospital who have confirmed CA-UTI to investigate the correlation between ABO type with the susceptibility of recurrent, reinfection and MDR reinfection CA-UTI in critically ill. 1730 patients were reviewed to screen patients for inclusion into the study,203 patients have confirmed CA-UTI using 2010 IDSA guideline definition.81patients meeting inclusion/exclusion criteria were enrolled. Patients were divided into two groups based on ABO type (O-group Vs. Non-O group). We considered a P value of < 0.05 as statistically significant.Results: Among 81 patients, 37 patients (45.6%) had O blood group type. Patients with O blood group type were associated with lower rate of recurrent CA-UTI (OR 0.28, 95% CI 0.085-0.952, P = 0.0414), multidrug resistant (MDR) organisms (OR 0.05, 95% CI 0.003-0.752, P = 0.0304), shorter ICU LOS (Est (SE): -0.024 (0.045), P = <0.001) and mechanical ventilation duration (Est. (SE): -0.41 (0.066), P = <0.001) compared with non-O blood group type. On the other hand, neither CA-UTI reinfection (OR 1.47, 95% CI 0.357-6.054, P = 0.5538) nor ICU mortality (OR 0.70, 95% CI 0.219-2.257, P = 0.5538) were statistically significant.Conclusion: Patients with non-O group type were statistically significant associated with higher rate of recurrent CA-UTI and MDRO. These data confirm the need for randomized controlled trials with a larger sample size to clarify and confirm our study findings.